Site-selective antibody modification by cysteine-to-lysine transfer (CLT)

Lead Research Organisation: University College London
Department Name: Chemistry

Abstract

With CRUK recently highlighting that 1 in 2 of us will have cancer in our lifetimes, the requirement for progress in developing new medicines and improved diagnostics for oncology is a high priority for our society. The current state of the art in chemotherapeutics still relies heavily on untargeted cytotoxins, leading to severe side-effects which are intolerable in many cases. In contrast, the attachment of cytotoxins to a delivery agent, which targets the 'warhead' specifically to the tumor, offers the enticing possibility of 'magic-bullet' chemotherapies. Antibody-Drug Conjugates (ADCs) represent amongst the most promising class of such drugs in development, with 3 ADCs achieving clinical approval in the last few years. However, it is widely considered that the molecular construction of ADCs currently is still far from optimal, and that new technologies in this area are urgently required to help enable them to achieve their clinical potential. Most notably current approaches employed to attach the cytotoxic drugs to the antibodies lead to a highly complex mixture of products. The result is a drug which contains a vast number of distinct species, each with a different pharmacological profile.
In this project we are proposing to pioneer a new chemical approach for the generation of ADCs, which attaches the drugs at specific locations on the antibody, generating superior homogeneous conjugates. Our strategy, crucially, will not require genetic engineering of the antibodies to incorporate reactive handles, and is thus applicable directly to native 'off-the-shelf' antibodies. This will maximise the accessibility of homogenous ADCs to researchers across the world and ensure that the production yields are maintained as high as possible, ultimately reducing the cost of these relatively complex biopharmaceuticals.
We will achieve goal this by targeting specific lysine amino-acids on the surface of the antibodies. This is a challenging aim as there are numerous lysines present; and as such we are proposing to develop new methodology, in which the conjugation reagent is guided to a specific location by a neighbouring cysteine amino-acid. This unprecedented cysteine-to-lysine transfer (CLT) approach will generate amide linkages between the antibody and the drug which are already extremely well characterised and known to be robustly stable in vivo. This will afford a high-level of confidence which will facilitate rapid uptake in the field.
Overall this CLT platform will represent an optimum approach for producing ADCs and facilitate the wider success of these exciting targeted therapies.

Planned Impact

This project aims to increase our capability to produce targeted cancer therapies, and thus improved patient healthcare is the main, long-term, prospective impact. By overcoming key limitations in the design and synthesis of ADCs this work will contribute to the broader success of these therapeutics going forward. By developing a homogeneous conjugation strategy that can be employed directly on native antibodies, forming clinically validated amide linkages, maximises the chances of this approach being taken-up into clinical products. It also ensures the costs are kept as low as possible, and will even allow existing clinical antibodies to be re-purposed as antibody conjugates.
The technology development described in this proposal will be carried out using Herceptin, which is an antibody used in the treatment of breast, oesophageal and stomach cancers. This will ensure the products we generate are of direct potential for future clinical development in these areas.
The high economic value associated with antibody conjugates, particularly for therapy and imaging applications, also reveals that our approach could have very significant economic impact. For example the ADC field alone is expected to be worth $10 billion by 2024. We will work closely with UCL Business to obtain IP protection at key moments in the project, to establish a proprietary platform which will incentivize the future investment required to pursue final healthcare products.
Throughout this project we will disseminate our findings widely, through publications, posters and seminars, with the aim of facilitating impact throughout the various scientific communities in which antibody conjugates play diverse roles.

Publications

10 25 50
 
Description To date we have discovered and published our initial results on the 'Cysteine-to-Lysine' (CLT) approach to the construction of antibody fragment conjugates. The method represents the first example of this novel approach - with the resultant highly stable, homogeneous antibody conjugates having broad potential applicability in the fields of chemistry, biology and medicine.
Exploitation Route We have published our initial results, so researchers in the area can use the methods to synthesise the reagents and construct antibody conjugates. We have also submitted a patent application, so pending its outcome we will be able to provide a commercialization strategy to translate the platform for industrial appllications e.g. antibody drug conjugates as targeted therapies.
Sectors Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology

 
Description C-Terminal Selective Ligation to Access Homogeneous Antibody Conjugates
Amount £444,295 (GBP)
Funding ID EP/T016043/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 08/2020 
End 08/2023
 
Description Conference talk 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact The PI gave a talk at internationally leading conference on antibody drug conjugates - World ADC London 2020, 3rd-4th March 2020.
Year(s) Of Engagement Activity 2020